New opioid disorder drug MCAM enters first human safety trial
NCT ID NCT07602335
First seen May 29, 2026 · Last updated Jun 11, 2026 · Updated 2 times
Summary
This early-phase trial tests the safety and effects of a new drug called MCAM in healthy adults. In Part A, 39 participants receive a single dose of MCAM or a placebo to measure blood levels and safety. In Part B, people who have used opioids before will test how quickly and how long MCAM blocks opioid effects. The goal is to find a safe dose and understand how the drug works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dr. Vince Clinical Research
Overland Park, Kansas, 66212, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.